Pilot Study of RR-HNK in OCD ((HNKO))

This double-blind, placebo-controlled trial (n=45) will assess the safety and efficacy of two doses of intravenous (2R,6R)-Hydroxynorketamine (RR-HNK) in adults with obsessive-compulsive disorder (OCD). Participants will receive either 17.5mg/70kg or 35mg/70kg of RR-HNK, or a placebo, via a single infusion.

Led by Dr Carolyn Rodriguez at Stanford University, this study aims to understand how RR-HNK affects the brain and whether it can reduce OCD symptoms.

Participants, aged 18–65, must have a confirmed OCD diagnosis and have either failed at least one prior standard OCD treatment (such as serotonin reuptake inhibitors or cognitive-behavioural therapy) or declined these treatments. EEG and behavioural tests will be conducted before and after the infusion to assess changes in OCD severity, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS). The trial is funded by the National Institutes of Health (NIH) and is expected to run from December 2024 to November 2029.

Topic Obsessive-Compulsive Disorder Neuroscience
Compound Ketamine Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Stanford University
Researchers at Stanford are exploring the potential of ketamine, MDMA and psilocybin by connecting neuroscience, psychiatry and anesthesiology.

National Institutes of Health
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.